Brain and Spinal Cord Lesions with Long-Term Total Artificial Heart Pumping

1998 ◽  
pp. 50-58 ◽  
Author(s):  
Jaromír Vašků
Keyword(s):  
Spinal Cord ◽  
Artificial Heart ◽  
Total Artificial Heart ◽  
Spinal Cord Lesions ◽  
Brain And Spinal Cord

Reoperative surgery in calves with a total artificial heart

1980 ◽  
Vol 3 (1) ◽  
pp. 24-29
Author(s):  
H. Fukumasu ◽  
D.B. Olsen ◽  
J.H. Lawson ◽  
A. Mochizuki ◽  
N. Daitoh ◽  
...  
Keyword(s):  
Artificial Heart ◽  
Surgical Techniques ◽  
Total Artificial Heart ◽  
Reoperative Surgery ◽  
Left Thoracotomy ◽  
Right Thoracotomy ◽  
The Right

Two surgical techniques have been developed in our laboratory to deal with identifiable problems in long-term artificial heart experiments. A right thoracotomy is used to deal with problems such as extensive bleeding, which occur in the immediate postoperative stage of the experiment, while a left thoracotomy is used in cases in Which the original implantation is preceded by more than one week, since extensive adhesions complicate the right thoracotomy at that stage. Pulmonary problems have been eliminated as a primary cause of difficulties after reoperation, but infection remains a serious problem.

scholarly journals Complete Correction of Brain and Spinal Cord Pathology in Metachromatic Leukodystrophy Mice

2021 ◽  
Vol 14 ◽  
Author(s):  
Emilie Audouard ◽  
Valentin Oger ◽  
Béatrix Meha ◽  
Nathalie Cartier ◽  
Caroline Sevin ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Gene Therapy ◽  
Metachromatic Leukodystrophy ◽  
Early Death ◽  
Lysosomal Storage ◽  
Adeno Associated Virus ◽  
Virus Serotype ◽  
Brain And Spinal Cord ◽  
Sulfatide Accumulation

Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder characterized by accumulation of sulfatides in both glial cells and neurons. MLD results from an inherited deficiency of arylsulfatase A (ARSA) and myelin degeneration in the central and peripheral nervous systems. Currently, no effective treatment is available for the most frequent late infantile (LI) form of MLD after symptom onset. The LI form results in rapid neurological degradation and early death. ARSA enzyme must be rapidly and efficiently delivered to brain and spinal cord oligodendrocytes of patients with LI MLD in order to potentially stop the progression of the disease. We previously showed that brain gene therapy with adeno-associated virus serotype rh10 (AAVrh10) driving the expression of human ARSA cDNA alleviated most long-term disease manifestations in MLD mice but was not sufficient in MLD patient to improve disease progression. Herein, we evaluated the short-term effects of intravenous AAVPHP.eB delivery driving the expression of human ARSA cDNA under the control of the cytomegalovirus/b-actin hybrid (CAG) promoter in 6-month-old MLD mice that already show marked sulfatide accumulation and brain pathology. Within 3 months, a single intravenous injection of AAVPHP.eB-hARSA-HA resulted in correction of brain and spinal cord sulfatide storage, and improvement of astrogliosis and microgliosis in brain and spinal cord of treated animals. These results strongly support to consider the use of AAVPHP.eB-hARSA vector for intravenous gene therapy in symptomatic rapidly progressing forms of MLD.

The Total Artificial Heart

1991 ◽  
Vol 2 (3) ◽  
pp. 587-597
Author(s):  
Lawrence E. Barker
Keyword(s):  
Artificial Heart ◽  
Total Artificial Heart ◽  
Thromboembolic Events ◽  
Bridge To Transplant ◽  
University Of Utah ◽  
Cardiac Assistance ◽  
Permanent Implants ◽  
Mechanical Devices ◽  
The University

In the early 1800s, an awareness of potential ventricular failure stimulated interest in artificial heart replacement. In 1937 the first total artificial heart (TAH) was implanted into the chest of a dog by Russian physicians. The primary driving force for mechanical cardiac assistance developed from the necessity for circulatory assistance in order to perform corrective cardiac surgery. In 1953 the first successful closure of an atrial septal defect using extracorporeal circulation was performed. During the following decade the concept of using mechanical devices to assist the failing heart was aggressively pursued. This culminated in the first implant of a TAH in a human in 1969 as a bridge to transplant. Clinical implant of the TAH as a permanent device was performed in 1982 by researchers at the University of Utah. This patient lived for 112 days. Three successive permanent implants were performed in Louisville, Kentucky, with one patient surviving for 620 days. All of these permanent TAH patients suffered from device-related complications including bleeding, infection, and thromboembolic events. It became apparent that the present configuration of the TAH with its external drive lines and large air console was not ideal for long-term support. In 1985 the first implant of the Symbion J-7-100 TAH (Jarvik-7) as a bridge to transplant was performed. This patient was supported by the device for 9 days and was successfully transplanted and discharged home. Since 1985 more than 170 patients have been bridged using the Symbion J-7 TAH with more than 70% of these patients being successfully transplanted. The incidence of thromboembolic events has dramatically reduced with better understanding of anticoagulation requirements. Infection continues to be the greatest potential complication with these patients. In spite of this, the pneumatic TAH has proved to be an adequate bridge to transplant device

Baylor Multi-Purpose One-Piece Total Artificial Heart (TAH) System for Short-Term to Long-Term Use

1993 ◽  
pp. 153-160 ◽  
Author(s):  
Motomi Shiono ◽  
Setsuo Takatani ◽  
Tatsuya Sasaki ◽  
Naoki Minato ◽  
Yukihiko Orime ◽  
...  
Keyword(s):  
Artificial Heart ◽  
Total Artificial Heart ◽  
Short Term

The Applicability of Experimental Experience with the Total Artificial Heart to its Clinical Use

1992 ◽  
Vol 15 (5) ◽  
pp. 307-311 ◽  
Author(s):  
J. Vašků ◽  
P. Urbánek ◽  
M. Dostál ◽  
Jan Vašků
Keyword(s):  
Clinical Application ◽  
Artificial Heart ◽  
Venous Pressure ◽  
Early Period ◽  
Total Artificial Heart ◽  
Blood Coagulation Disorders ◽  
Clinical Use ◽  
Long Term Experiments ◽  
Long Term Experiment

Long-term experiments with the total artificial heart (TAH) are a source of valuable knowledge for later clinical application. Our observations result from 66 long-term experiments on calves and one goat ranging from 30 to 314 days, which have shown the main possible complications in the early period (one month) and later in the experiment. Problems until the second month of pumping concern the clinical pendant of the TAH as a bridge for transplantation, i.e. surgical problems, blood coagulation disorders, infection etc. Later problems are high venous pressure or arterial hypertension, infection with septic thromboembolization, mineralization of the driving diaphragm, etc., and are more closely comparable to the conditions of permanent clinical use of the TAH. Faultless surgery, device function and the regimen of pumping are essential factors in every long-term experiment, just as in clinical application. Infection is a threat throughout any experiment, as in clinical cases. The TNS-BRNO-VII/clin/80 TAH has been implanted in six patients.

Long-Term Survival and Outgrowth of Mechanically Engineered Nervous Tissue Constructs Implanted Into Spinal Cord Lesions

2006 ◽  
Vol 0 (0) ◽  
pp. 060215071050001 ◽  
Author(s):  
Akira Iwata ◽  
Kevin D. Browne ◽  
Bryan J. Pfister ◽  
John A. Gruner ◽  
Douglas H. Smith
Keyword(s):  
Spinal Cord ◽  
Nervous Tissue ◽  
Spinal Cord Lesions ◽  
Term Survival ◽  
Long Term Survival ◽  
Tissue Constructs

Histopathology Image Analysis in Two Long-Term Animal Experiments with Helical Flow Total Artificial Heart

2016 ◽  
Vol 40 (12) ◽  
pp. 1137-1145 ◽  
Author(s):  
Jiri Wotke ◽  
Pavel Homolka ◽  
Jaromír Vasku ◽  
Petr Dobsak ◽  
Petra Palanova ◽  
...  
Keyword(s):  
Image Analysis ◽  
Artificial Heart ◽  
Animal Experiments ◽  
Helical Flow ◽  
Total Artificial Heart ◽  
Histopathology Image Analysis

scholarly journals Identification of Genetic Loci Controlling the Characteristics and Severity of Brain and Spinal Cord Lesions in Experimental Allergic Encephalomyelitis

2000 ◽  
Vol 157 (2) ◽  
pp. 637-645 ◽  
Author(s):  
Russell J. Butterfield ◽  
Elizabeth P. Blankenhorn ◽  
Randall J. Roper ◽  
James F. Zachary ◽  
R.W. Doerge ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Experimental Allergic Encephalomyelitis ◽  
Allergic Encephalomyelitis ◽  
Genetic Loci ◽  
Spinal Cord Lesions ◽  
Brain And Spinal Cord ◽  
Experimental Allergic
Sign in / Sign up

Export Citation Format

Share Document